KLBF – Small cell lung cancer medicine innovation

KLBF – Small cell lung cancer medicine innovation Kalbe Farma (KLBF) has just released a medicine for first-line extensive small cell lung cancer called Serplulimab on March 9, 2024. The medicine will be used for patients with small cell lung cancer which when compared to patients with non-small cell lung cancer only ranges from 13-15%, but the life expectancy is much lower (around 7% in 5 years). It is expected that with the use of these medicine and combined with chemotherapy, the patients survival rate will increasing, around 43.1% in stage 4 cancer patients. The launch of Serplulimab is a collaboration with Shanghai Henlius Biotech after obtaining a distribution permit from BPOM RI in December 2023. Furthermore, the medicine will be marketed to Southeast Asia, the Middle East and North Africa. (Source : Kontan)